JMIR Cancer

Patient-centered innovations, education, and technology for cancer care, cancer survivorship, and cancer research.

Editor-in-Chief:

Matthew Balcarras, MSc, PhD, Scientific Editor at JMIR Publications, Ontario, Canada


Impact Factor 2.7 CiteScore 5.9

JMIR Cancer (JC, ISSN: 2369-1999) is a peer-reviewed journal focusing on education, innovation and technology in cancer care, cancer survivorship and cancer research, and participatory and patient-centred approaches. This journal also includes research on non-Internet approaches to improve cancer care and cancer research.

We invite submissions of original research, viewpoints, reviews, tutorials, and non-conventional articles (e.g. open patient education material and software resources that are not yet evaluated but are free for others to use/implement). 

In our "Patients' Corner," we invite patients and survivors to submit short essays and viewpoints on all aspects of cancer. In particular, we are interested in suggestions on improving the health care system and suggestions for new technologies, applications and approaches (this section has no article processing fees).

JMIR Cancer is indexed in PubMed Central and PubMedScopusDOAJ, MEDLINE, and the Emerging Sources Citation Index (Clarivate)

JMIR Cancer received a Journal Impact Factor of 2.7 according to the latest release of the Journal Citation Reports from Clarivate, 2025.

With a CiteScore of 5.9 (2024), JMIR Cancer is a Q2 journal in the field of Oncology, according to Scopus data.

Recent Articles

Article Thumbnail
Innovations and Technology in Cancer Research

Technology is changing the way the world communicates and how we learn, remember, and transform information. The ascendancy of the internet has dramatically altered the landscape of health information access and seeking behaviors. This transformation is embodied by the concept of digital health literacy (DHL) and the need for interventions that improve DHL.

|
Article Thumbnail
Methods in Cancer Research

Patients with metastatic breast cancer (MBC) experience significant quality-of-life decrements, but there are few supportive care interventions specifically designed for this group that significantly improve quality of life. Ecological momentary assessment (EMA) and related ecological momentary interventions (EMIs) may be particularly beneficial for patients with MBC. However, no studies have previously examined the use of EMIs in the context of metastatic cancer.

|
Article Thumbnail
Innovations and Technology in Cancer Care

To support physicians in focusing on relevant information during melanoma treatment, it is essential to design information systems (ISs) that integrate into their workflow.

|
Article Thumbnail
Breast Cancer

Artificial intelligence (AI) is increasingly used to generate medical content, yet its performance in delivering clinically relevant and reliable information remains underexplored, especially in complex areas such as breast cancer.

|
Article Thumbnail
Patients' Corner: Patient Perspectives on Cancer, Technology, and the Patient Journey

Adolescents and young adults with cancer have distinct developmental and psychosocial needs that require care models bridging pediatric and adult oncology systems. While survival outcomes have improved, there is growing recognition of the need to strengthen coordinated care, psychosocial support, and survivorship services. In Ontario, regional and community-based cancer programs play a central role in delivering accessible care and are well-positioned to support adolescents and young adults closer to home. However, variation in infrastructure, workforce capacity, and system-level coordination influences how developmentally appropriate oncology care is implemented. Existing literature has focused on tertiary and specialty centers, highlighting the need to leverage and strengthen regional systems, providers, and community resources to support high-quality adolescent and young adult cancer care.

|
Article Thumbnail
Clinical Cancer Research

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but their safety profile in patients with thymic epithelial tumors (TETs) remains poorly characterized due to the rarity of these malignancies.

|
Article Thumbnail
Innovations in Cancer Diagnostic and Decision Support

Screening for clinical trials is challenging for clinicians due to its time-consuming and repetitive nature. The rise of artificial intelligence (AI) offers an opportunity to improve screening productivity and reproducibility. Pancreatic cancer is characterized by increasing incidence, poor survival outcomes, and an urgent need for improved management strategies.

|
Article Thumbnail
Nutrition, Physical Activity, Healthy Lifestyle for Cancer Patients and Survivors

Cognitive impairments, a prevalent quality-of-life concern in breast cancer (BC), are particularly pronounced in women having undergone adjuvant chemotherapy. These impairments—affecting executive function, attention, and processing speed—are often underdiagnosed, with no established treatments. Exercise is a potential intervention to mitigate cancer-related cognitive impairment (CRCI). Since virtual care delivery is feasible, remotely delivered exercise interventions for CRCI management in patients with BC may be explored.

|
Article Thumbnail
Innovations and Technology in Cancer Care

Accurate esophageal cancer staging relies on 18F fluorodeoxyglucose positron emission tomography (18F FDG-PET), but its interpretation is complex and time-intensive. This diagnostic burden is exacerbated by significant workforce shortages in both radiology and surgery, thus necessitating automated support systems. The emergence of advanced large language models (LLMs) has raised expectations for their potential to fulfill this role in complex medical tasks.

|
Article Thumbnail
Clinical Cancer Research

Bone metastasis is a prevalent complication of malignant tumors, often resulting in restricted mobility, severe pain, and diminished quality of life.

|
Article Thumbnail
Research Letter

Our study describes the characteristics of remote patient monitoring use among commercially insured patients with cancer from 2019 to 2023.

|

We are working in partnership with